Journal article
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
Abstract
Background To determine the recommended phase II dose (RP2D) and assess the safety, pharmacokinetics (PKs) and pharmacodynamics of RO4929097in combination with temsirolimus. Methods Escalating doses of RO4929097 and temsirolimus were administered at three dose levels. Patients received once daily oral RO4929097 on a 3 days on/4 days off schedule every week, and weekly intravenous temsirolimus. Blood samples were collected for PK analysis. …
Authors
Diaz-Padilla I; Hirte H; Oza AM; Clarke BA; Cohen B; Reedjik M; Zhang T; Kamel-Reid S; Ivy SP; Hotte SJ
Journal
Investigational New Drugs, Vol. 31, No. 5, pp. 1182–1191
Publisher
Springer Nature
Publication Date
October 2013
DOI
10.1007/s10637-013-0001-5
ISSN
0167-6997
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAmyloid Precursor Protein SecretasesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzazepinesCalcium-Binding ProteinsFatigueFemaleHumansIntercellular Signaling Peptides and ProteinsMaleMembrane ProteinsMiddle AgedMucositisNeoplasmsProtein Kinase InhibitorsReceptor, Notch3Receptors, NotchSerrate-Jagged ProteinsSirolimus